Research programme: human cytomegalovirus inhibitors - GPC Biotech/4SC

Drug Profile

Research programme: human cytomegalovirus inhibitors - GPC Biotech/4SC

Alternative Names: HCMV kinase inhibitors - GPC Biotech/4SC

Latest Information Update: 23 Jan 2007

Price : $50

At a glance

  • Originator 4SC; GPC Biotech AG
  • Class Small molecules
  • Mechanism of Action Phosphotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cytomegalovirus infections

Most Recent Events

  • 26 Apr 2006 No development reported - Preclinical for Cytomegalovirus infections treatment in Germany (unspecified route)
  • 02 Mar 2005 Axxima Pharmaceuticals has been acquired and merged into GPC Biotech AG
  • 03 Sep 2002 Preclinical trials in Cytomegalovirus infections in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top